Jong Eun Lee Email & Phone Number

Seoul, South Korea

Shaperon(http://www.shaperon.com/eng/main/) is a clinical stage biotech company developing novel inflammasome inhibitors and was listed in KOSAQ(378800) in 2022. I work for licensing developing medicines.

Seoul, South Korea

Started Bio Venture business

Seoul, South Korea

Head of Business Development in Bukwang Pharmaceuticals together with CNS marketing

Jung-gu, Seoul, Korea

• Marketing
• Launched ENSTILUM®(psoriasis medicine) and differentiated it from existing portfolios, reaching 20% of market share at 1st year of launch and preparing for launch of ADTRAZA®(atopic dermatitis biologics) in line with.
• Create and execute key stakeholder management plan and roadmaps for new biologics setup for registration and market access
• Set up brand plans that aligns and includes practical tools to implicate plans in Korea through multiple workshop/meetings with relevant staff
• Raised market leadership in saturated psoriasis & atopic dermatitis market by setting new strategy to focus on clinic market by sharing real world cases
• Headed project to enhance digital activities including webinars, engaged emails, and websites for seamless message delivery during COVID-19 period

Seoul, South Korea

• Managed 30 commercial staff (20 sales reps., 3 district sales managers, 1 key account manager, 1 sales force effectiveness manager, 2 product managers, 1 assistant product manager, 1 market access/public affairs.
• Led segmentation and target setting for sales representatives and develop new incentive scheme and target setting system
• Accelerated sales growth by setting focus bricks and follow up message delivery in target focus bricks

Seoul, South Korea

• Marketing
• Launched BRINTELLIX®(antidepressant) and completed listing in major hospitals within 6 months and AZILECT®(Parkinson’s disease drug) by doubling target sales
• Increased LEXAPRO®(antidepressant) market leadership and constantly increased EBIXA®(Alzheimer’s’ disease drug) market share every year despite generic competition
• Received 2015 Lundbeck Global Commercial Conference Award for best business achievement Business Development
• Coordinating all partnership issues including KPI setting, sales force deployment, message delivery, management meetings, and service fee payment
• Completed license in deal with Teva for AZILECT® and complete business cases and got local launch approval of AZILECT® and Brintellix

Sydney, Australia

• Was responsible for pre-marketing activities of AZILECT® in Australia
• Led the patient familiarization program of AZILECT® before the launch and doubled the patient target enrollment

• Executed all tasks related to marketing, market access, regulatory affairs, scientific affairs, price listing, and clinical trials

Seoul, South Korea

• Experienced in oncology, hematology, neurology, and dermatology field
• Responsible for BETAFERON®(multiple sclerosis medicine) and established a new market as the first product and managed orphan drug business in expanding reimbursement to 100%
• Responsible for digital marketing of Bayer Korea’s oral contraceptive; DIANE®, managed corporate communications and PR of Bayer Korea

Seoul, South Korea

• Accomplished the registration and price listing for reimbursement
• Coordinated the global licensing of FACTIVE®(antibiotics, first Korean medicine approved by US FDA) to GSK

Master Of Business Administration - Mba

Master'S Degree, Pharmacy

Majored medicinal chemistry

Bachelor'S Degree, Pharmacy